{"organizations": [], "uuid": "0cf501771bf981967572f61510aac6e17ca328fc", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "uk.finance.yahoo.com", "main_image": "https://s1.yimg.com/bt/api/res/1.2/M7vS95b2fvSzHFeFStPk0A--/YXBwaWQ9eW5ld3NfbGVnbztxPTc1O3c9NjAw/http://l.yimg.com/os/mit/media/m/social/images/social_default_logo-1481777.png", "site_section": "https://uk.finance.yahoo.com/news/category-europe/?format=rss", "section_title": "European Business News | Financial News - Yahoo! Finance UK", "url": "https://uk.finance.yahoo.com/news/acacia-pulls-ipo-european-biotechs-150553335.html", "country": "GB", "title": "Acacia pulls IPO as European biotechs caught in U.S downdraft", "performance_score": 0, "site": "yahoo.com", "participants_count": 0, "title_full": "Acacia pulls IPO as European biotechs caught in U.S downdraft", "spam_score": 0.0, "site_type": "news", "published": "2015-10-16T18:05:00.000+03:00", "replies_count": 0, "uuid": "0cf501771bf981967572f61510aac6e17ca328fc"}, "author": "", "url": "https://uk.finance.yahoo.com/news/acacia-pulls-ipo-european-biotechs-150553335.html", "ord_in_thread": 0, "title": "Acacia pulls IPO as European biotechs caught in U.S downdraft", "locations": ["U.S"], "entities": {"persons": [], "locations": [], "organizations": []}, "highlightText": "", "language": "english", "persons": [], "text": "Tip : Use comma (,) to separate multiple quotes. Learn more... \nFri, Oct 16, 2015, 16:48 BST - UK Markets closed Acacia pulls IPO as European biotechs caught in U.S downdraft Reuters - UK Focus â€“ 42 minutes ago \n* U.S (Other OTC: UBGXF - news ) . sell-off on drug pricing fears rattles investors \n* IPO would have been second largest in UK since 2005 \n* Other biotechs also postponing offerings due to volatility (Adds comment from Symetis on \"perfect storm\" in market) \nBy Ben Hirschler and John Miller \nLONDON/ZURICH, Oct (HKSE: 3366-OL.HK - news ) 16 (Reuters) - Acacia Pharma (IPO-ACAC.L), a specialist in finding new uses for existing medicines, said on Friday it had postponed plans to float in London due to adverse market conditions. \nAcacia is the latest European biotech company to be caught in a downdraft from the U.S. pharmaceutical and biotechnology sector, which has suffered a major sell-off on mounting concerns about pressure on drug prices. \nBritain's Shield Therapeutics (IPO-SHIE.L) also postponed its planned initial public offering (IPO) last week and Swiss medical technology group Symetis (IPO-SYMS.S) put its planned IPO on ice on Sept. 28. \nAcacia's decision not to go ahead with its flotation is a particular blow given the size of the planned offering. \nThe aim had been to raise up to 150 million pounds ($232 million), according to a person familiar with the matter, which would have made it the second-biggest biotech IPO in London since 2005, after the 200 million pounds raised by Circassia (Stuttgart: 23863607.SG - news ) Pharmaceuticals last year. \nShield Therapeutics, meanwhile, had been looking to raise as much as 110 million pounds. \n\"It (Other OTC: ITGL - news ) is disappointing that our intended IPO, which has received a good level of interest and positive reaction from investors both in the UK and internationally, has coincided with this current period of market uncertainty,\" Acacia founder and Chief Executive Julian Gilbert said. \nThe decision reflected recent high levels of volatility and uncertainty in global equity markets generally and in the pharmaceuticals sector in particular, the company said. \nA much smaller IPO from Evgen Pharma (IPO-EVGE.L) did get away successfully in London on Friday, with the company raising 7 million pounds. \nSwiss firm Symetis said specific healthcare sector concerns came on top of uncertainties over future U.S. interest rates, worries about China's growth prospects and an implosion in global commodities. \n\"All these factors together - it was a perfect storm,\" a spokesman said. \"In the end, we found that investors' risk appetite had all but evaporated.\" \nMany investors fear the drugs industry faces a moment of reckoning as political pressure on the sector mounts, amid criticism of price hikes slapped on both new and older medicines in the United States, the biggest and most profitable market. \nThe issue has been highlighted by Democratic presidential candidate Hillary Clinton and was in the spotlight again this week when Valeant Pharmaceuticals International (NYSE: VRX - news ) was subpoenaed by U.S. prosecutors seeking details on its drug pricing practices. \nBiotech stocks have been on a roll since the start of 2013, fuelled by optimism about new medicines reaching the market, but recent heavy selling has erased all of 2015's gains on the Nasdaq (NasdaqGS: NDAQ - news ) biotechnology index. \nIn the United States, recently withdrawn biotech and pharma IPOs include planned for offerings for Revo Biologics, Par Pharmaceutical, Neurosigma and Syncardia. \n($1 = 0.6478 pounds) (Editing by Jane Merriman and Pravin Char)", "external_links": [], "published": "2015-10-16T18:05:00.000+03:00", "crawled": "2015-10-16T18:49:40.972+03:00", "highlightTitle": ""}